The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis
Open accessAbstract
BACKGROUND: Extensively drug-resistant tuberculosis has been reported in 45 countries, including countries with limited resources and a high burden of tuberculosis. We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among patients who were referred for individualized outpatient therapy in Peru. METHODS: A total of 810 patients were referred for free individualized therapy, including drug treatment, resective surgery, adverse-event management, and nutritional and psychosocial support. We tested isolates from 651 patients for extensively drug-resistant tuberculosis and developed regimens that included five or more drugs to which the infecting isolate was not resistant. RESULTS: Of the 651 patients tested, 48 (7.4%) had extensively drug-resistant tuberculosis; the remaining 603 patients had multidrug-resistant tuberculosis. The patients with extensively drug-resistant tuberculosis had undergone more treatment than the other patients (mean [+/-SD] number of regimens, 4.2+/-1.9 vs. 3.2+/-1.6; P<0.001) and had isolates that were resistant to more drugs (number of drugs, 8.4+/-1.1 vs. 5.3+/-1.5; P<0.001). None of the patients with extensively drug-resistant tuberculosis were coinfected with the human immunodeficiency virus (HIV). Patients with extensively drug-resistant tuberculosis received daily, supervised therapy with an average of 5.3+/-1.3 drugs, including cycloserine, an injectable drug, and a fluoroquinolone. Twenty-nine of these patients (60.4%) completed treatment or were cured, as compared with 400 patients (66.3%) with multidrug-resistant tuberculosis (P=0.36). CONCLUSIONS: Extensively drug-resistant tuberculosis can be cured in HIV-negative patients through outpatient treatment, even in those who have received multiple prior courses of therapy for tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69573-1 · Cited by 1,732
Fox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
Shah, N. S., Wright, A., Bai, G.-H., Barrera, L., Boulahbal, F., Martín-Casabona, N., Drobniewski, F., Gilpin, C., Havelková, M., Lepe, R., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1303.061400 · Cited by 583
Espinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507
Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru
Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J., Alcántara, F., Sánchez, E., Sarria, M., Becerra, M., Fawzi, M. C. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022928 · Cited by 489
Self-citationEvolution and spread of antibiotic resistance
Normark, B. H., & Normark, S. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01026.x · Cited by 440
Fluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
Programmes and principles in treatment of multidrug-resistant tuberculosis
Mukherjee, J. S., Rich, M. L., Socci, A. R., Joseph, J. K., Virú, F. A., Shin, S. S., Furin, J. J., Becerra, M. C., Barry, D. J., Kim, J. Y., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15496-2 · Cited by 333
Self-citationTreatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol
Condos, R., Rom, W. N., & Schluger, N. W. (1997) · The Lancet · doi:10.1016/s0140-6736(96)12273-x · Cited by 316
Frieden, T. R. (1996) · JAMA · doi:10.1001/jama.276.15.1229 · Cited by 295
Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.
Laserson, K. F., Thorpe, L. E., Leimane, V., Weyer, K., Mitnick, C. D., Riekstiņa, V., Zarovska, E., Rich, M., Fraser, H., Alarcon, E., et al. (2005) · PubMed · Cited by 292
Self-citationLeimane, V., Riekstina, V., Holtz, T. H., Zarovska, E., Skripconoka, V., Thorpe, L. E., Laserson, K. F., & Wells, C. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17786-1 · Cited by 279
Global Tuberculosis Control: WHO Report 2011
Williams, C. (2012) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2012.00928.x · Cited by 265
Yew, W. W., Chan, C. K., Chau, C. H., Tam, C. M., Leung, C. C., Wong, P. C., & Lee, J. (2000) · Chest · doi:10.1378/chest.117.3.744 · Cited by 231
Suárez, P. G., Floyd, K., Portocarrero, J., Alarcón, E., Rapiti, E., Ramos, G., Bonilla, C., Sabogal, I., Aranda, I., Dye, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08830-x · Cited by 211
Self-citationBasu, S., Andrews, J. R., Poolman, E. M., Gandhi, N. R., Shah, N. S., Moll, A., Moodley, P., Galvani, A. P., & Friedland, G. H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61636-5 · Cited by 201
Nathanson, E., Gupta, R., Huamani, P., Leimane, V., Pasechnikov, A., Tupasi, T. E., Vink, K., Jaramillo, E., & Espinal, M. (2004) · PubMed · Cited by 189
XDR-TB in South Africa: No Time for Denial or Complacency
Singh, J. A., Upshur, R., & Padayatchi, N. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040050 · Cited by 184
Psychiatric issues in the management of patients with multidrug-resistant tuberculosis.
Vega, P. S. C., Sweetland, A. C., Acha, J., Castillo, H., Guerra, D., Smith-Fawzi, M. C., & Shin, S. S. (2004) · PubMed · Cited by 173
Self-citationSuárez, Floyd, Portocarrero, & Alarcon (2002) · The Lancet · Cited by 166
Frieden, T. R., Sherman, L. F., Maw, K. L., Fujiwara, P. I., Crawford, J. T., Nivin, B., Sharp, V., Hewlett, D., Brudney, K. F., Alland, D., et al. (1996) · PubMed · Cited by 141
Furin, J. J., Mitnick, C. D., Shin, S. S., Bayona, J. N., Becerra, M. C., Singler, J. M., de Alcântara, F. F., Castañieda, C., Sanchez, E., Acha, J., et al. (2001) · PubMed · Cited by 138
Self-citationMatteelli, A., Migliori, G. B., Cirillo, D. M., Centis, R., Girardi, E., & Raviglione, M. C. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.857 · Cited by 124
First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons
Coninx, R., Mathieu, C., Debacker, M., Mirzoev, F., Ismaelov, A., Haller, R. D., & Meddings, D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08341-x · Cited by 114
Park, S. K., Kim, C. T., & Song, S. D. (1998) · PubMed · Cited by 108
Somocurcio, J. G., Sotomayor, A. R., Shin, S. S., Portilla, S., Valcarcel, M., Guerra, D., & Furin, J. J. (2006) · Thorax · doi:10.1136/thx.2005.051961 · Cited by 89
Self-citationDonald, P. R. (2001) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540152029954 · Cited by 66
Nurses as providers of emotional support to patients with MDR‐TB
Chalco, K., Wu, D.-H., Mestanza, L., et al. (2006) · International Nursing Review · doi:10.1111/j.1466-7657.2006.00490.x · Cited by 62
Self-citationAntimicrobial Therapy of Tuberculosis: Justification for Currently Recommended Treatment Regimens
Mitchison, D. A. (2004) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2004-829503 · Cited by 59
Mycobacterium vaccae immunotherapy for treating tuberculosis
de Bruyn, G., & Garner, P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001166 · Cited by 58
Tuberculosis drug development pipeline: progress and hope
Spigelman, M., & Gillespie, S. H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68388-8 · Cited by 58
Extensively Drug-Resistant Tuberculosis: Are We Learning from History or Repeating It?
HAMILTON, C. D., Sterling, T. R., Blumberg, H. M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/519292 · Cited by 38
Park, S.-K., Cho, S., Lee, I.-H., Jeon, D.-S., Hong, S.-H., Smego, R. A., & Cho, S.-N. (2007) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2006.12.004 · Cited by 34
Farnia, P., Masjedi, M. R., Mohammadi, F., Tabarsei, P., Farnia, P., Mohammadzadeh, A. R., Baghei, P., Varahram, M., Hoffner, S., & Velayati, A. A. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01435-07 · Cited by 34
Cited by
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Self-citationHelb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914
Lawn, S. D., & Zumla, A. I. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62173-3 · Cited by 751
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Caminero, J. A., Sotgiu, G., Zumla, A., & Migliori, G. B. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70139-0 · Cited by 574
Orenstein, E. W., Basu, S., Shah, N. S., Andrews, J. R., Friedland, G. H., Moll, A. P., Gandhi, N. R., & Galvani, A. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70041-6 · Cited by 540
Metadata
- Authors
- Mitnick, C. D., Shin, S. S., Seung, K. J., Rich, M. L., Atwood, S. S., Furin, J. J., Fitzmaurice, G. M., Alcantara Viru, F. A., Appleton, S. C., Bayona, J. N., Bonilla, C. A., Chalco, K., Choi, S., Franke, M. F., Fraser, H. S. F., Guerra, D., Hurtado, R. M., Jazayeri, D., Joseph, K., Llaro, K., Mestanza, L., Mukherjee, J. S., Muñoz, M., Palacios, E., Sanchez, E., Sloutsky, A., & Becerra, M. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-08-07
- Volume
- 359
- Issue
- 6
- Pages
- 563-574
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2136694704
- Cited by
- 402
- References
- 35
- FWCI
- 33.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.